Biomarker-Guided therapy aims to outperform standard treatment in advanced esophageal cancer
NCT ID NCT07709533
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial investigates whether tailoring treatment based on specific biomarkers can improve outcomes for people with advanced esophageal squamous cell carcinoma that has spread. Participants are randomly assigned to receive either standard chemotherapy plus a PD-1 inhibitor or the same backbone therapy plus additional treatments guided by three biomarker tests. The study aims to see if the precision approach extends the time without cancer progression compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy (paclitaxel and cisplatin) plus a PD-1 inhibitor, with or without additional targeted therapies based on biomarker results
- What this could lead to
- If successful, this approach could show that matching additional treatments to a patient's specific biomarkers improves survival over standard therapy for advanced esophageal cancer.
- What could go wrong
- This is a Phase 2 trial, so results are preliminary and may not lead to a new standard of care. The precision strategy is complex and may not benefit all biomarker subgroups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VALID MESH CONDITIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sub-i
Guangdong, GUANGZHOU, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.